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Objectives: To estimate the number of patients with
recurrent respiratory papillomatosis currently managed in
secondary and tertiary health care in the UK and the
frequency of its treatment with radiofrequency cold ablation
(CoblationTM).
Design: Cross-sectional survey of ENT consultants in the
UK with validation using Hospital Episode Statistics (HES)
inpatient data.
Setting: Online survey.
Participants: ENT consultants in the UK.
Main outcomemeasures: Number of recurrent respiratory
papillomatosis patients currently managed in acute care in
the UK and frequency of use of Coblation.
Results: A total of 283 ENT consultants from 128 UK
NHS healthcare trusts and health boards completed the
online survey. Responses were received from 86% of
surveyed organisations, and an estimated 45% of all ENT
consultants in UK. The estimated number of recurrent
respiratory papillomatosis patients from the cross-sec-
tional survey was 918 (at August 2015) which included
730 patients in England. The number of recurrent
respiratory papillomatosis patients in England estimated
from Hospital Episode Statistics (2014/15 financial year)
was up to 741. A total of 42 Coblation procedures
conducted in the UK were identified from the cross-
sectional survey; 36 were conducted in England com-
pared with 34 identified from Hospital Episode Statistics.
Conclusions: The numbers of recurrent respiratory papil-
lomatosis patients and Coblation procedures identified in
England from a cross-sectional survey and Hospital Episode
Statistics were in broad agreement. Our study estimated 1.42
recurrent respiratory papillomatosis patients per 100 000 in
the generalUKpopulation.We also estimated thatCoblation
procedures accounted for 3% of interventional treatments
conducted in the UK recurrent respiratory papillomatosis
population.
Recurrent respiratory papillomatosis is a relatively rare
condition, but has a significant impact on patients and their
families as it requires repeated anaesthetic procedures to
achieve symptomatic control.1 The most basic estimates of
cost for recurrent respiratory papillomatosis suggest that
even though it is a rare condition, the cost of care is relatively
high.2 It has been difficult to identify the prevalence for
recurrent respiratory papillomatosis as there is no specific
diagnosis code3 or established registry. Previously, a ques-
tionnaire of members’ experience was sent to the British
Association of Paediatric Otolaryngologists to identify
treatment trends.4 That study had limited scope (recurrent
respiratory papillomatosis affects both children and adults)
and limited coverage (41 respondents, 39% response rate, 27
departments, 103 patients) and did not aim to estimate
prevalence.
In 2012, the UK National Institute for Health and Care
Excellence (NICE) published Interventional Procedures
Guidance on Radiofrequency cold ablation for respiratory
papillomatosis.5 This guidance highlighted a lack of safety
and efficacy evidence to support its use in the treatment
of recurrent respiratory papillomatosis and recommended
that Coblation procedures be conducted with special
arrangements for clinical governance, consent and audit
or research.
The primary aim of this study was to estimate the total
number of children and adults with recurrent respiratory
papillomatosis who are currently managed in the UK to
provide a baseline for further epidemiological study. A
secondary aim was to inform interventional procedure
guidance development, in particular the extent to which
radiofrequency cold ablation (CoblationTM, Smith and
Nephewplc,Huntingdon,UK)was being used as a treatment
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option. To do this, we administered a national survey to ENT
consultants and compared responses with estimates from
routine administrative data from the Hospital Episode
Statistics database.
Materials and methods
Ethical considerations
Only aggregated totals of patients and procedures from a 12-
month period were collected in the national survey and
analysis of Hospital Episode Statistics. No patient identifi-
able information was used, and no ethical approvals were
sought.
National recurrent respiratory papillomatosis survey –
Study participants
A structured online questionnaire was developed in Sur-
veyMonkey (SurveyMonkey Inc., Palo Alto, CA, USA)
(Fig. 1). A link to the survey was emailed to the clinical
governance leads in 156 acute NHS trusts in England, 14
NHS Boards in Scotland, seven Health Boards in Wales and
five Health & Social Care Trusts in Northern Ireland, who
were requested to forward the survey details to all ENT
consultants within their organisation. The survey was open
for 4 weeks (July–August 2015). The Chief Medical Officers
in Scotland, Wales and Northern Ireland distributed the
survey (via email) to all Medical Directors within their
Fig. 1. Recurrent respiratory papillomatosis survey developed in survey monkey.
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devolved administrations to encourage completeness. ENT
UK also supported the survey by distributing (via email) the
details of the survey to every ENT UK member (including
honorary members) and sent a reminder 1 week before the
survey closing date.
National recurrent respiratory papillomatosis survey –
Statistical analysis
Responses were collated in SurveyMonkey and exported in a
Microsoft Excel file. ENT UK provided the total number of
ENT consultant members in each home nation, from which
the consultant completion rate was estimated. Summary
statistics were calculated for all responses; those expressed as
‘more than n’ were treated as n + 1. When calculating the
proportion of recurrent respiratory papillomatosis patients
(response to Question 3, Fig. 1) who had received at least one
interventional procedure (Question 4), values exceeding 100%
were considered as typographical errors and interpreted as
100%. Reported use of other interventions (Question 7)
without a frequency for their use in the last 12 months
(Question 6) was interpreted as historic interventions con-
ducted prior to August 2014. All data analyses were conducted
using the statistical programming language R.6
Hospital Episode Statistics analysis – Data sources and
study population
A retrospective cohort study was conducted using data from
the 2014/15 inpatient data set from Hospital Episode
Statistics.7 An estimate of the number of episodes of care
concerning recurrent respiratory papillomatosis was con-
sidered as the number of episodes containing at least one of
the International Classification of Diseases 10th revision
(ICD-10) diagnosis codes defined in Table 1, appearing in
any of the 20 diagnosis fields.
The number of patients was deduced from the number of
unique pseudoanonymised patient identifiers (Hospital
Episode Statistics field PSEUDO_HESID) in episodes of
care for recurrent respiratory papillomatosis. ICD10 codes
D10/D14 can also be used to indicate other non-recurrent
respiratory papillomatosis diagnoses (e.g. polyps in the
airway). Because recurrent respiratory papillomatosis is
recurrent, for the purposes of this study, the number of
patients with recurrent respiratory papillomatosis was
defined as those patients having more than one admission
with the specified ICD10 codes during the period of interest.
The number of Coblation treatments conducted in this
population was considered as the number of admissions
containing the Office of Population Censuses and Surveys
Classification of Interventions and Procedures (OPCS-4)
supplementary code for method of approach ‘Y10.1 –
Coblation’ appearing in any of the 24 procedure fields.
Results
Of the 182 individual organisations contacted with details of
the national recurrent respiratory papillomatosis survey, a
total of 157 responded; 128 completed the survey and a
further 29 indicated the survey was not applicable to their
organisation. A total of 289 responses from individual ENT
consultants were received from the online survey. Six of these
responses were excluded from further analysis because the
respondent did not practice in the UK. The numbers of
organisations responding from each Home Nation, with
estimates of completeness, are shown in Table 2. The
numbers of individual ENT consultants responding from
each Home Nation, and estimates of completeness (using
ENT UK reported consultant members per Home Nation as
the denominator), are also shown in Table 2.
The total number of recurrent respiratory papillomatosis
patients identified from the survey responses was 918,
reported by 150 ENT consultants (with the remaining 133
ENT consultants reporting no recurrent respiratory papil-
lomatosis patients currently under their own care). A total of
730 (79.5%) of these patients were reported from ENT
consultants in England, 126 (13.7%) from Scotland, 53
(5.8%) from Wales and 9 (1.0%) from Northern Ireland.
Based on a population size of 64.6 million,8 the lower
estimate of recurrent respiratory papillomatosis in the UK is
1.42 per 100 000. The 918 patients mentioned in the
responses were assumed to be unique individuals.
From ENT consultants reporting recurrent respiratory
papillomatosis patients currently under their care, the
median [lower quartile (Q1), upper quartile (Q3)] number
of recurrent respiratory papillomatosis patients per consul-
tant was 3.5 (2,6) with range 1–69. Of the 918 recurrent
respiratory papillomatosis patients reported to be managed
Table 1. List of ICD10 codes used to identify recurrent respiratory
papillomatosis episodes of care
ICD10 code (description)
D10 (Benign neoplasm of mouth and pharynx)
D14.1 (Benign neoplasm of middle ear and respiratory system:
larynx)
D14.2 (Benign neoplasm of middle ear and respiratory system:
trachea)
D14.3 (Benign neoplasm of middle ear and respiratory system:
bronchus and lung)
D14.4 (Benign neoplasm of middle ear and respiratory system:
respiratory system, unspecified)
B97.7 (Papillomavirus as the cause of diseases classified to other
chapters)
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in theUK, 479 (52.2%)were reported to have had at least one
therapeutic interventional procedure and 350 (38.1%)
required surveillance endoscopy only, in the past year.
One hundred and twenty-five ENT consultants conducted
a median (Q1,Q3) of 4 (2,8) with range 1–30 interventional
procedures in recurrent respiratory papillomatosis patients
within the last 12 months. The proportions using each type
of intervention and the total number of times they were used
are described in Table 3.
Of the 42 Coblation procedures, 36 were conducted in
England (by 12 ENT consultants), four in Wales (four ENT
consultants) and two in Scotland (one ENT consultant).
Five ENT consultants reported using other interventional
procedures: three reported use of intralesional injections of
cidofovir, one used monopolar diathermy, and one stated
endoscopy without intervention.
An additional thirteen ENT consultants conducted other
procedures in their recurrent respiratory papillomatosis
patients prior to August 2014; these were specified via free
text as: cidofovir, HPV vaccine unspecified and antireflux
therapy reported by two ENT consultants, and topical
mitomycin C, topical agents unspecified, vaccination, bal-
loon dilatation, KTP laser, CO2 laser, referral for laser, and
endoscopic keel for acquiredWeb each reported by one ENT
consultant.
The estimates of the number of recurrent respiratory
papillomatosis patients and the number of Coblation
treatments conducted in these patients identified from
Hospital Episode Statistics are described in Table 4.
Discussion
Synopsis of key/new findings
The results of this study represent the largest and most
complete response to a nationwide survey of recurrent
respiratory papillomatosis in the UK. The high response rate
achieved with this survey would not have been possible
without the full support of ENT UK and the Chief Medical
Officers of the devolved nations. The reason for the survey
was to inform future national guidance, through National
Institute for Health and Care Excellence, for interventional
procedures for recurrent respiratory papillomatosis and to
Table 2. Number of responses and percentage survey completeness (highlighted in bold) by organisation and by ENT specialty
England Scotland Wales Northern Ireland Total (UK)
No. of organisations contacted 156 14 7 5 182
No. of organisations with at least 1 survey completed 110 8 6 4 128
No. of organisations replied with ‘Not applicable’* 27 1 1 0 29
Total responding 137 9 7 4 157
Organisational survey completeness (%) 87.8 64.3 100.0 80.0 86.3
No. of individual ENT consultant responses 233 24 21 5 283
ENT consultant completeness (%) 45.6 40.7 19.2 61.8 44.9
*Survey not disseminated further due to lack of ENT consultants in organisation.
Table 3. Total number of ENT consultants conducting specified
types of recurrent respiratory papillomatosis intervention and the
total number of times they were conducted in the last 12 months
(August 2014–July 2015)
Total no. of ENT
consultants using
procedure (%)
Total no. of
procedures
conducted (%)
Biopsy for histology 80 (64.0) 367 (29.1)
Microdebrider 73 (58.4) 474 (37.5)
Laser 48 (38.4) 209 (16.5)
Cold steel surgery
(forceps)
42 (33.6) 151 (12.0)
Radiofrequency
cold ablation
(Coblation)
17 (13.6) 42 (3.3)
Other 5 (4.0) 20 (1.6)
Table 4. Results of Hospital Episode Statistics analysis (2014/
15 M13 – inpatient universe)
Estimate
Episodes 8906
Patients 7360
Patients with repeat admissions
(RRP patients)
741
Procedures from patients
with repeat admission
which included OPCS
Classification of
Interventions and
Procedures code Y10.1
(‘Coblation’)
34
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assess the potential future benefits of investment in a
procedure register.
Our study identified a population of 918 patients with
recurrent respiratory papillomatosis currently being man-
aged in the UK acute hospital sector. This recurrent
respiratory papillomatosis population size is comparable
with previous studies conducted in other countries. Esti-
mated recurrent respiratory papillomatosis rates in the
United States are between 1 and 4 per 100 000 of the general
population,9 which, when extrapolated to the general
population size of the UK, provides an estimate of between
646 and 2584 people with recurrent respiratory papillo-
matosis in the UK. Although the estimated recurrent
respiratory papillomatosis population of 918 is at the lower
end of the range predicted by applying the US rates to UK
population size, it is still within the same order of magnitude
and as such, it is an entirely plausible result. This survey will
provide a baseline estimate of prevalence for further
epidemiological studies in the future, for example the effect
of the National HPV vaccination program in the UK in
recurrent respiratory papillomatosis. Genital warts, like
recurrent respiratory papillomatosis, are caused by HPV6/
11. With the introduction of HPV vaccination in Australia,
genital warts have reduced significantly.10
To encourage completion of the survey, particular atten-
tionwas given tomaking the survey focussed and concise. To
avoid additional burden upon respondents, a decision was
made to conduct a survey of prevalence, and as such, we did
not attempt to quantify incidence of newly diagnosed
patients in the preceding 12 months.
The number of Coblation procedures conducted in
England, as obtained by the national survey, is in broad
agreement with the results from Hospital Episode Statistics
inpatient data. This may be explained by the availability of
the specific supplementary Office of Population Censuses
and Surveys Classification of Interventions and Procedures
code Y10.1 which indicates ‘Coblation’.
Strengths of the study
One hundred and eighty-two individual NHS healthcare
trusts and health boards in the UK were approached with
the national recurrent respiratory papillomatosis survey,
and approximately of these 86% responded. General use of
inpatient administrative data to determine epidemiology
of any disease is likely to provide a lower estimate;
however, we were able to validate estimates of recurrent
respiratory papillomatosis and frequency of use of Cobla-
tion obtained from our survey using Hospital Episode
Statistics inpatient data due to high admission/interven-
tion rate associated with the recurrent respiratory papil-
lomatosis condition.
Limitations of the study
In administering the online survey, responses were received
from 86% of organisations but only 45% of ENT consultants
in the UK. From ENT UK membership numbers, it is likely
that some consultants did not respond because they had no
recurrent respiratory papillomatosis patients under their
care. The total number of recurrent respiratory papillo-
matosis patients identified from our national online survey
should not be scaled up to provide a representative figure of
prevalence from the entire UK. Instead, the total number of
918 recurrent respiratory papillomatosis patients should be
considered as a lower estimate of the number patients
managed with the disease in the UK.
In analysing Hospital Episode Statistics data, we
acknowledge that ‘D10’ and ‘D14’ subchapters of ICD10
(‘Benign neoplasm of mouth & pharynx’ and ‘Benign
neoplasm of middle ear & respiratory system’) are used for
other conditions such as polyps in the airway, as well as
recurrent respiratory papillomatosis. Some clinical coders
appear to include the additional ICD-10 code B97.7
[‘Papillomavirus as cause of disease (NEC)’] to specify
recurrent respiratory papillomatosis patients more clearly;
however, this approach is not widely adopted across the
NHS. In an attempt to restrict our Hospital Episode
Statistics analysis to likely recurrent respiratory papillo-
matosis patients, we defined recurrent respiratory papillo-
matosis patients as those with multiple hospital admissions
during a given year. This approach was likely to remove
the majority of patients with non-recurrent respiratory
papillomatosis diagnoses, however, and would also exclude
true recurrent respiratory papillomatosis patients with a
single hospital admission – this trade-off was considered
acceptable. In terms of clinical coding of procedures, the
Office of Population Censuses and Surveys Classification
of Interventions and Procedures code for Coblation
(supplementary code for method of approach, Y10.1
‘Coblation’) is specific to the intervention. However, as
Coblation can be also used during polypectomy (removal
of polyps from airway), its use does not make the searches
of administrative data specific to recurrent respiratory
papillomatosis. Results obtained from Hospital Episode
Statistics are also limited by potential missing data where
none of the specified diagnosis or procedure codes were
used.
Conclusion
Within the limitations of the survey, a lower estimate of the
prevalence of recurrent respiratory papillomatosis patients
currently requiring management in the secondary and
tertiary health sector appears to be in the order of 1.42 per
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100 000 UK population. This is in line with previous studies
conducted in other countries. Our survey completed by 86%
of NHS healthcare trusts and health boards estimated 918
patients with recurrent respiratory papillomatosis were
managed in the UK acute hospital sector in the last year.
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Keypoints
• A total of 150 ENT consultants reportedmanaging 918
patients with recurrent respiratory papillomatosis. 133
reported no patients with recurrent respiratory papil-
lomatosis. This might imply that some departments
have adopted a strategy to allowdesignated consultants
to take themajority of cases hence allow an expertise to
develop for this relatively rare condition.
• ENT surgeons who manage patients with recurrent
respiratory papillomatosis conducted a median of 4
procedures per annum.
• Microdebrider was the most common treatment used.
• Only 3.3% of procedures for recurrent respiratory
papillomatosis used radiofrequency cold ablation
(Coblation).
• The use of adjuvant medical therapy reported was
minimal.
• Recurrent respiratory papillomatosis prevalence
appears to be near 1.42/100 000 UK population.
Acknowledgements
The national recurrent respiratory papillomatosis surveywas
supported by the National Institute for Health and Care
Excellence, and theChiefMedicalOfficers in Scotland,Wales
and Northern Ireland and ENT UK. Special thanks to all the
clinical governance leads within acute trusts in England,
NHS Boards in Scotland, Health Boards in Wales and
Health and Social Care Trusts in Northern Ireland who
disseminated the survey to ENT consultants within their
organisation.
Conflict of interest
None to declare.
References
1 Stamataki S., Nikolopoulos T.P., Korres S. et al. (2007) Juvenile
recurrent respiratory papillomatosis: still a mystery disease with
difficult management. Head Neck 29, 155–162
2 Donne A.J. & Clarke R. (2010) Recurrent respiratory papillomato-
sis: an uncommon but potentially devastating effect of human
papillomavirus in children. Int. J. STD AIDS 21, 381–385
3 Silverberg M.J., Thorsen P., Lindeberg H. et al. (2004) Clinical
course of recurrent respiratory papillomatosis in Danish Children.
Arch. Otolaryngol. Head Neck Surg. 130, 711–716
4 Tasca R.A., McCormick M. & Clarke R.W. (2006) British Associ-
ation of Paediatric Otorhinolaryngology members experience with
recurrent respiratory papillomatosis. Int. J. Pediatr. Otorhinolaryn-
gol. 70, 1183–1187
5 National Institute of Health and Care Excellence (2012). Interven-
tional Procedures Guidance (IPG434): Radiofrequency cold abla-
tion for respiratory papillomatosis. URL https://www.nice.org.uk/
guidance/ipg434 [accessed on 2 June 2016]
6 The R Foundation (2015). The R Project for Statistical Computing.
URL https://www.r-project.org/ [accessed on 2 June 2016]
7 Hospital Episode Statistics (2015). Admitted Patient Care England.
URL www.hscic.gov.uk [accessed on 2 June 2016]
8 Office of National Statistics (2015). Population. URL http://
ons.gov.uk/ons/taxonomy/index.html?nscl=Population [accessed
on 2 June 2016]
9 Larson D.A. & Derkay C.S. (2010) Epidemiology of recurrent
respiratory papillomatosis. APMIS. 118, 450–454
10 Chow E.P., Read T.R., Wigan R. et al. (2015) Ongoing decline in
genital warts among young heterosexuals 7 years after the Aus-
tralian human papillomavirus (HPV) vaccination programme. Sex
Transm. Infect. 91, 214–219
Estimated UK prevalence and management of RRP 91
© 2016 The Authors. Clinical Otolaryngology Published by John Wiley & Sons Ltd  Clinical Otolaryngology 42, 86–91
